vs
Side-by-side financial comparison of Ameris Bancorp (ABCB) and Bio-Techne (TECH). Click either name above to swap in a different company.
Ameris Bancorp is the larger business by last-quarter revenue ($314.4M vs $295.9M, roughly 1.1× Bio-Techne). Ameris Bancorp runs the higher net margin — 35.1% vs 12.8%, a 22.3% gap on every dollar of revenue. On growth, Ameris Bancorp posted the faster year-over-year revenue change (10.0% vs -6.4%). Over the past eight quarters, Bio-Techne's revenue compounded faster (4.2% CAGR vs 2.3%).
Ameris Bancorp is an American bank holding company headquartered in Atlanta, Georgia. Through its bank subsidiary, Ameris Bank, the company operates full-service branches in Georgia, Alabama, Florida, North Carolina and South Carolina, and mortgage-only locations in Georgia, Alabama, Florida, North Carolina, South Carolina, Virginia, Maryland, and Tennessee. The company offers online and mobile banking options for both consumers and businesses.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
ABCB vs TECH — Head-to-Head
Income Statement — Q1 FY2026 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $314.4M | $295.9M |
| Net Profit | $110.5M | $38.0M |
| Gross Margin | — | 64.6% |
| Operating Margin | — | 18.4% |
| Net Margin | 35.1% | 12.8% |
| Revenue YoY | 10.0% | -6.4% |
| Net Profit YoY | — | 68.3% |
| EPS (diluted) | $1.63 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $314.4M | — | ||
| Q4 25 | $307.1M | $295.9M | ||
| Q3 25 | $314.2M | — | ||
| Q2 25 | $300.7M | $317.0M | ||
| Q1 25 | $285.9M | $316.2M | ||
| Q4 24 | $290.8M | $297.0M | ||
| Q3 24 | $283.8M | $289.5M | ||
| Q2 24 | $300.6M | $306.1M |
| Q1 26 | $110.5M | — | ||
| Q4 25 | $108.4M | $38.0M | ||
| Q3 25 | $106.0M | — | ||
| Q2 25 | $109.8M | $-17.7M | ||
| Q1 25 | $87.9M | $22.6M | ||
| Q4 24 | $94.4M | $34.9M | ||
| Q3 24 | $99.2M | $33.6M | ||
| Q2 24 | $90.8M | $40.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 62.7% | ||
| Q1 25 | — | 67.9% | ||
| Q4 24 | — | 65.3% | ||
| Q3 24 | — | 63.2% | ||
| Q2 24 | — | 66.4% |
| Q1 26 | — | — | ||
| Q4 25 | 45.9% | 18.4% | ||
| Q3 25 | 43.6% | — | ||
| Q2 25 | 47.4% | -7.5% | ||
| Q1 25 | 39.5% | 12.2% | ||
| Q4 24 | 43.3% | 16.0% | ||
| Q3 24 | 44.4% | 13.8% | ||
| Q2 24 | 42.1% | 15.0% |
| Q1 26 | 35.1% | — | ||
| Q4 25 | 44.2% | 12.8% | ||
| Q3 25 | 33.7% | — | ||
| Q2 25 | 36.5% | -5.6% | ||
| Q1 25 | 30.8% | 7.1% | ||
| Q4 24 | 42.5% | 11.7% | ||
| Q3 24 | 35.0% | 11.6% | ||
| Q2 24 | 30.2% | 13.3% |
| Q1 26 | $1.63 | — | ||
| Q4 25 | $1.59 | $0.24 | ||
| Q3 25 | $1.54 | — | ||
| Q2 25 | $1.60 | $-0.11 | ||
| Q1 25 | $1.27 | $0.14 | ||
| Q4 24 | $1.35 | $0.22 | ||
| Q3 24 | $1.44 | $0.21 | ||
| Q2 24 | $1.32 | $0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $172.9M |
| Total DebtLower is stronger | — | $260.0M |
| Stockholders' EquityBook value | $4.1B | $2.0B |
| Total Assets | $28.1B | $2.5B |
| Debt / EquityLower = less leverage | — | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $172.9M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $162.2M | ||
| Q1 25 | — | $140.7M | ||
| Q4 24 | — | $177.5M | ||
| Q3 24 | — | $187.5M | ||
| Q2 24 | — | $152.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | $260.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | — | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M |
| Q1 26 | $4.1B | — | ||
| Q4 25 | $4.1B | $2.0B | ||
| Q3 25 | $4.0B | — | ||
| Q2 25 | $3.9B | $1.9B | ||
| Q1 25 | $3.8B | $2.0B | ||
| Q4 24 | $3.8B | $2.1B | ||
| Q3 24 | $3.7B | $2.1B | ||
| Q2 24 | $3.6B | $2.1B |
| Q1 26 | $28.1B | — | ||
| Q4 25 | $27.5B | $2.5B | ||
| Q3 25 | $27.1B | — | ||
| Q2 25 | $26.7B | $2.6B | ||
| Q1 25 | $26.5B | $2.6B | ||
| Q4 24 | $26.3B | $2.7B | ||
| Q3 24 | $26.4B | $2.7B | ||
| Q2 24 | $26.5B | $2.7B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ABCB
Segment breakdown not available.
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
